RNAC Cartesian Therapeutics, Inc.
Healthcare$6.45-4.44%ClosedMarket Cap: $189.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.22
P/S
111.73
EV/EBITDA
-1.36
DCF Value
$3.80
FCF Yield
-39.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-621.0%
Operating Margin
-5144.5%
Net Margin
-8550.6%
ROE
194.1%
ROA
-52.6%
ROIC
-31.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $78.0K | 100.0% | $-26.5M | $-39.2M | $— | — |
| Q4 null | $947.0K | 100.0% | $-21.9M | $-92.6M | $— | — |
| FY null | $2.8M | 100.0% | $-86.7M | $-130.3M | $— | — |
| Q3 null | $452.0K | -2731.2% | $-21.1M | $-35.9M | $— | — |
| Q2 null | $298.0K | 100.0% | $-21.8M | $15.9M | $— | — |
| Q1 null | $1.1M | 100.0% | $-21.9M | $-17.7M | $— | — |
| Q4 null | $-759.0K | 100.0% | $-26.7M | $-10.3M | $— | — |
| FY null | $38.9M | 100.0% | $-43.9M | $-77.4M | $— | — |
| Q3 null | $387.0K | 100.0% | $-17.6M | $-24.2M | $— | — |
| Q2 null | $33.4M | 100.0% | $13.8M | $13.8M | $— | — |
| Q1 null | $5.8M | 100.0% | $-13.3M | $-56.8M | $— | — |
| Q4 2023 | $8.3M | 100.0% | $-36.3M | $-177.7M | $-41.56 | — |